Topiramate Capsule, Extended Release
Product Images NDC 0832-1072

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 0832-1072). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Upsher-smith Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Topiramate 01)

Chemical structure of the active ingredient Topiramate, shown as a molecular diagram with atoms and bonds illustrating its chemical composition.*

FDA Label Image

Figure 1 (Topiramate 02)

A Kaplan-Meier curve graph showing cumulative rates for time to first seizure comparing Topiramate 50 mg/day (N=234) and Topiramate 400 mg/day (N=236) over a 500-day period. The y-axis represents cumulative seizure rates, while the x-axis shows time in days. The graph includes a statistical significance value (p = 0.0002).*

FDA Label Image

Figure 2 (Topiramate 03)

A bar chart displaying the proportion of patients (%) versus reduction in seizure frequency from baseline (%). It compares placebo and Topiramate Extended-Release Capsules 200 mg/day across groups with different seizure reduction ranges (Worse, 0-<25, 25-<50, 50-<75, 75-100). Black bars represent Topiramate and white bars represent placebo.*

FDA Label Image

Figure 3 (Topiramate 04)

A bar chart comparing the change from baseline to double-blind phase in average monthly migraine period rate (MPR) for placebo and Topiramate doses 50 mg/day, 100 mg/day, and 200 mg/day, based on two studies. The chart shows mean reductions with error bars for each group, with statistically significant decreases at higher doses indicated by asterisks.*

FDA Label Image

Principal Display Panel (25 mg Capsule Bottle Label)

Label for Topiramate Extended-Release Capsules 25 mg, oral capsules for once-daily dosing. The package contains 30 capsules and is manufactured for Upsher-Smith Laboratories, LLC. The label includes dosage instructions, storage conditions, child-resistant packaging information, and a barcode.*

FDA Label Image

Principal Display Panel (50 mg Capsule Bottle Label)

Label for Topiramate Extended-Release Capsules 50 mg by Upsher-Smith Laboratories, LLC. The label indicates each capsule contains 50 mg of topiramate with a 30-capsule package. It includes storage instructions, dosage guidance, a barcode, and a pharmacist note to dispense the medication guide separately.*

FDA Label Image

Principal Display Panel (100 mg Capsule Bottle Label)

Topiramate Extended-Release Capsules 100 mg label showing one capsule dosage strength from Upsher-Smith Laboratories, LLC. The label includes dosing instructions, storage conditions, and packaging information for a bottle containing 30 capsules. The label displays the NDC 0832-1074-30 and a barcode.*

FDA Label Image

Principal Display Panel (150 mg Capsule Bottle Label)

Label for Topiramate Extended-Release Capsules 150 mg by Upsher-Smith Laboratories, LLC. The label highlights once-daily dosing and instructs pharmacists to dispense the medication guide with each prescription. It indicates the package contains 30 capsules and includes storage instructions and a barcode.*

FDA Label Image

Principal Display Panel (200 mg Capsule Bottle Label)

Label for Topiramate Extended-Release Capsules 200 mg by Upsher-Smith Laboratories, LLC. The label indicates a 30-capsule bottle with once-daily dosing. It includes storage instructions, child-resistant packaging information, and a barcode, with the 200 mg strength prominently displayed in pink.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.